Audit of clinical practice in the use of incretin mimetic agents for the management of patients with type 2 diabetes
Open accessAbstract
Abstract The objective of this audit was to compare treatment outcomes in patients on dipeptidyl peptidase (DPP)‐4 inhibitors and glucagon‐like peptide‐1 receptor (GLP‐1R) agonists within a hospital clinic setting, and to identify factors that might influence their response to treatment. We undertook a retrospective audit of 118 consecutive patients who received either a DPP‐4 inhibitor or a GLP‐1R agonist as add‐on to existing oral hypoglycaemic agent therapy. Primary clinical outcomes compared were change in HbA1c and weight. The clinical characteristics of patients who responded with both weight loss and improvement in HbA1c were compared to those who did not. The results showed that more patients (73.6%) were on a GLP‐1R agonist; 57% of patients on a GLP‐1R agonist lost weight and had improved HbA1c compared to 40% of patients on a DPP‐4 inhibitor. The mean reduction in HbA1c was 8.4mmol/mol with a mean weight loss of 2.6kg. There were good correlations between the initial HbA1c and decline in HbA1c in both treatment groups. In all, 68.3% of patients on additional insulin treatment improved HbA1c while 46.3% improved in terms of both weight and HbA1c. Patients not on insulin responded better to treatment (OR 1.96; p=0.047) with these agents. It was concluded that good metabolic control can be achieved if these agents are used judiciously. The DPP‐4 inhibitors improve HbA1c but are weight neutral, while the GLP‐1R agonists cause both weight loss and improvements in HbA1c. The addition of insulin under specialist supervision can be beneficial. Copyright © 2013 John Wiley & Sons. Practical Diabetes 2013; 30(4): 159–162
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The few studies that have evaluated real-world effectiveness of GLP-1 RAs have yielded inconsistent results.
“The few studies that have evaluated real-world effectiveness of GLP-1 RAs have yielded inconsistent results.”
From Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK (2022) · cites this paper as [28]
The Patients and methods section describes a clinical-practice audit of GLP-1 receptor agonists, so this paper is an example of a real-world effectiveness study. But it does not establish that such studies were few or that their results were inconsistent. Instead, the Discussion says its findings were in line with clinical trials, and the limitations passage says the direction of change was similar to published audits. (LLM, conf=0.80)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · see citing works
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962 · see citing works
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923 · see citing works
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · see citing works
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · see citing works
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · see citing works
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 876 · see citing works
Nauck, M. A., Bartels, E., Ørskov, C., Ebert, R., & Creutzfeldt, W. (1993) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.76.4.8473405 · Cited by 505 · see citing works
Gut hormones and diabetes mellitus
Creutzfeldt, W., & Nauck, M. (1992) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610080206 · Cited by 176 · see citing works
Kielgast, U. L., Krarup, T., Holst, J. J., & Madsbad, S. (2011) · Diabetes Care · doi:10.2337/dc11-0096 · Cited by 165 · see citing works
Beta cell mass in diabetes: a realistic therapeutic target?
Meier, J. J. (2008) · Diabetologia · doi:10.1007/s00125-008-0936-9 · Cited by 155 · see citing works
Thong, K. Y., Jose, B., Sukumar, N., CULL, M. L., Mills, A. P., Sathyapalan, T., Shafiq, W., Rigby, A. S., Walton, C., Ryder, R. E. J., et al. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01393.x · Cited by 97 · see citing works
The Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit
Ryder, R. E. J., Thong, K. Y., CULL, M. L., Mills, A., Walton, C., & Winocour, P. H. (2010) · Practical Diabetes · doi:10.1002/pdi.1522 · Cited by 33 · see citing works
Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis
Amori, R. E., Lau, J., & Pittas, A. G. (2007) · JAMA · doi:10.1001/jama.298.2.194 · Cited by 12 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- Amori RE, et al. Efficacy and safety of incretin ther- apy in type 2 diabetes. JAMA 2007;298:194-206.
Cited by
Sorted by citations
Weiss, T., Yang, L., Carr, R. D., Pal, S., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002517 · Cited by 152 · see citing works
Weiss, T., Carr, R. D., Pal, S., Yang, L., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2020) · Patient Preference and Adherence · doi:10.2147/ppa.s277676 · Cited by 126 · see citing works
Liraglutide therapy in obese people with type 2 diabetes — Experience of a weight management centre
Elkhenini, H., New, J. P., Summers, L. K. M., & Syed, A. A. (2014) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.12.009 · Cited by 3 · see citing works
Review of clinical use of glucagon‐like peptide‐1 in the management of type 2 diabetes
Rushworth, G. F., Connelly, J., Laing, W., Maskrey, B. H., Nicholas, F. M., & MacRury, S. M. (2014) · Practical Diabetes · doi:10.1002/pdi.1886
- Authors
- Dhesi, B., Chauhan, H., & Basu, A.
- Affiliations
- Birmingham City Hospital (GB)
- Corresponding author
- Basu, Ansu
- ORCID
- Basu, Ansu
- Venue
- Practical Diabetes
- Publisher
- Wiley
- Published
- 2013-05
- Volume
- 30
- Issue
- 4
- Pages
- 159-162
- ISSN
- 1357-8170 (ISSN-L)
- 2047-2897
- 2047-2900
- OpenAlex
- W2049860443
- Cited by
- 4
- References
- 15
- Citations by year
- 2022: 1 · 2020: 1 · 2014: 2
- FWCI
- 0.53
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Practical Diabetes (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- type 2 diabetes, incretin mimetics, DPP-4 inhibitors, GLP-1 receptor agonists, HbA1c, weight loss, insulin therapy, adjunctive therapy, oral antidiabetic drugs, glycemic control
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
